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Abstract

On August 15, 2005, the Food and Drug Administration (FDA) and the Association of American Medical Colleges released a joint report that examines
possible steps to accelerate drug discovery and development. The report, entitled Drug Development Science: Obstacles and Opportunities for Collaboration
Among Academia, Industry and Government, is the product of a two-day conference among leaders from the pharmaceutical industry, academia, and FDA. The
goal of the conference and the report was to explore means of overcoming the
high failure rate for tentative drug candidates.
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A High-Level Report on Accelerating
Drug Discovery and Development
in the United States
On August 15, 2005, the Food and Drug
Administration (FDA) and the Association of
American Medical Colleges released a joint
report that examines possible steps to accelerate
drug discovery and development. The report,
entitled Drug Development Science: Obstacles and
Opportunities for Collaboration Among Academia,
Industry and Government, is the product of a
two-day conference among leaders from the
pharmaceutical industry, academia, and FDA.
The goal of the conference and the report
was to explore means of overcoming the high
failure rate for tentative drug candidates.
The report explores issues relating to
FDA’s Critical Path initiative, including:
Baltimore

•

The challenges in translating biomedical
knowledge and the rapidly growing
number of potential disease targets into
validated targets for drug discovery

•

The importance of identifying and validating
clinical biomarkers in both animal models
and humans, and of validating biomarkers
as surrogate end-points; and

•

The need to reduce inefficiency in
late phase clinical trials by use of new
techniques and approaches to improve
trial design and operations
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The report concluded that there are several
important opportunities to accelerate
drug discovery and development. Among
the major recommendations are that
government, academia, and the pharmaceutical
industry should work together to:
•
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Develop collaborative mechanisms
to enable sharing of toxicology data
across industry and the FDA

•

Establish an inventory of validated biomarkers

•

Create a consortium to analyze and
learn from failed clinical trials

•

Identify and propose to Congress new regulatory
incentive policies for small market drugs

•

Establish a public-private partnership to carry
out whole genome association studies and
deposit the data in the public domain

In the past year, FDA has encouraged an
active dialogue with industry regarding ways
to enhance the drug approval process, and
this report describes an important set of
policy questions and possible solutions.
FDA /AAMC Joint Report

EUROPE

EU Parliament Proposes Changes to EU
Draft Regulation on Compulsory Licensing
of Patented Pharmaceutical Products
On July 19, 2005, the EU Parliament published a
report proposing changes to the EU Commission’s
draft regulation on compulsory licensing. Following
the WTO General Council Decision of August
30, 2003, the draft regulation provides a twolevel procedure to lift EU patent protection of
pharmaceuticals so that generics manufacturers
can export them to developing countries. First, an
eligible importing country (or, with such a country’s
approval, a non-governmental organization or a
United Nations body) has to notify the WTO (or, in
case or a non-WTO member, the EU Commission)
of its intention to use the system. Second, any
person (e.g., generics producers) can then apply
to the competent EU Member State authorities
for a compulsory patent license to manufacture
and export the pharmaceutical product in
question. Except in emergency situations, the
application can only be made if the applicant tried
unsuccessfully for 30 days to obtain a negotiated
license from the patent holder. The EU Parliament
proposal would allow the Commission to establish
criteria determining the level of remuneration
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for the patent holder. Overall, it reflects a more
favorable approach towards compulsory licensing
by widening the scope of eligible importing
countries (no longer limited to WTO members)
and by relaxing the application-related procedural
requirements. However, the draft regulation
may still be modified by other EU institutions.
EU Parliament Report

US Supreme Court
issues opinion with
potentially enormous
implications for pharmaceutical research
and development

Amended German Medicines
Act Enters into Force
The 14th Amendment of the German Medicines
Act entered into force at the end of August
2005. This implements various EC Directives
relating to human tissue quality and safety and
herbal and human medicinal products, and
amends the Cure Advertisement Act (HWG).
Unfortunately, the amended HWG does not provide
the degree of liberalization of the drug advertisement
market that had been expected. The provisions
relating to the advertisement of non-prescription
but prescribable drugs (for example, Antazida and
H2 receptor blockers) have been expanded and the
number of diseases for which drug advertisement
outside expert circles (essentially, physicians and
pharmacists) is forbidden has now been restricted
to severe infectious diseases, malicious neoplasm,
addiction diseases and illnesses connected to
pregnancy and post-pregnancy. However, the
permitted range of advertisement activities has
not been significantly enlarged: the advertisement
of ethical drugs, for example, remains excluded
outside expert circles. In addition, effective as
of April 1, 2006, misleading and/or suggestive
advertising relating to plastic surgery is prohibited.
Medicines Act Amendment

INTELLECTUAL PROPERTY
UNITED STATES

Supreme Court Broadens Infringement
Safe Harbor for Drug R&D
In June, the Supreme Court issued an opinion in
Merck v. Integra that has potentially enormous
implications for pharmaceutical research and
development. By more broadly interpreting a
“safe harbor” from infringement, the Court may
have effectively immunized a significant portion
of drug research, at the expense of owners of
patents relating to drug targets, lead compounds,
discovery methods and, possibly, research tools.
As a result, universities, biotech companies
and big pharma may all wish to reassess their
US patent strategies and research activities.
The Merck v. Integra case centered on a statutory
exemption from infringement of a “patented

invention . . . solely for uses reasonably related to
the development and submission of information
under a Federal law” regulating drugs. The Court
of Appeals for the Federal Circuit had previously
held that this exemption in the Hatch-Waxman Act
was narrowly tailored and permitted “premarket
approval activity conducted for the sole purposes
of sales after patent expiration” (Hoechst-Roussel v.
Lehman (1997)) in order to “facilitate the immediate
entry of safe, generic drugs into the marketplace
upon expiration of a pioneer drug patent” (Integra
Lifesciences v. Merck (2003).) However, the Federal
Circuit ruled that it did not “encompass drug
development activities far beyond those necessary”
for FDA approval; “globally embrace all experimental
activity that at some point, however attenuated,
may lead to an FDA approval process;” or “reach
any exploratory research that may rationally form a
predicate for future FDA clinical tests”. The Federal
Circuit Court further warned that expansion of
the exemption “to include [such] activities would
effectively vitiate . . . biotechnology tool patents”
and “swallow the whole benefit of . . . some
categories of biotechnological inventions” (Integra).
However, the Supreme Court disagreed—at
least in part. Reversing the decision of the Federal
Circuit, it held that the exemption “extends to all
uses of patented inventions that are reasonably
related to the development and submission of
any information” to the FDA; that this “necessarily
includes preclinical studies of patented compounds
that are appropriate for submission to the FDA in
the regulatory process;” and that there “is simply no
room in the statute for excluding certain information
from the exemption on the basis of the phase of
research in which it is developed or the particular
submission in which it could be included.” On the
other hand, it held that “[b]asic scientific research
on a particular compound, performed without the
intent to develop a particular drug or a reasonable
belief that the compound will cause the sort of
physiological effect the researcher intends to induce”
is not protected. Although the Court specifically
declined to address research tool patents, it left the
question open as to whether they were exempted.
While it is clear that the scope of the exemption
has now been expanded—uses in preclinical
investigations, uses that do not result in FDA
submissions and uses unrelated to pre-expiration
submissions for a generic drug may fall within
it—its breadth remains unclear. Until further
clarification is received from the Federal Circuit
and, perhaps, the Supreme Court, owners of
patents relating to drug targets, lead compounds,
discovery methods and research tools may
wish to reassess their US patent strategies and
research activities, both in terms of the value of
their patent rights and the risks of infringement.
Merck v. Integra (2005)
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EUROPE

UK Ratifies Revised European
Patent Convention

subject to additional guidance by the courts. In
the meantime, the clarification it offers and the
attempt to harmonize with the approach of the
European Patent Office (EPO) is welcomed.

In July 2005, the UK became the fourteenth
member state to ratify the amendments to
the 1973 European Patent Convention (EPC),
agreed by diplomatic conference in 2000.

In the Matter of CFPH LLC

The revised EPC aims to adapt ‘the existing
1973 EPC to more effectively promote
innovation and economic growth within Europe’,
integrating developments in international patent
law—in particular the TRIPS Agreement and
the Patent Law Treaty. It is now expected
to take effect not before late 2007.

ANTITRUST/COMPETITION

The UK ensured compliance with the amended
EPC provisions with the passing of the 2004 Patent
Act in July 2004. A number of the key provisions
of this Act entered into force on January 1, 2005.
These impact upon remedies in entitlement
proceedings, compensation of employees for certain
inventions, threats of infringement proceedings,
costs and expenses in infringement proceedings
and enforcement of damages. A further set of
provisions, including those relating to co-ownership,
patent office opinions and security for costs, entered
into force on October 1, 2005. The remaining
provisions shall enter into force when the revised
EPC takes effect, ensuring greater consistency
and conformity with the practice of the EPO.
2000 EPC
Patents Act 2004

UK Patent Office Issues New Patentability
Assessment Practice Notice
In light of two recent judgments from the High
Court, the Patent Office has issued a new Practice
Notice advising of the approach its examiners shall
now take to the examination of patentability.
It advises that examiners should first look at the
substance of the claim as a whole and identify the
new and non-obvious advance in the art. They should
then determine whether this advance is in fact new
and obvious (and capable of industrial application),
in light of the description of “invention” as set out in
Article 52 of the EPC. Finally, they should consider
whether the new and non-obvious element identified
falls under the category of excluded matter, as
set out in the 1977 Patents Act (as amended).
While the Office considered that the new
approach should be applied with “immediate”
effect, it does not materially affect the boundary
of what is patentable. Each application shall
continue to be assessed on its merits and account
shall be taken of arguments put forward by the
applicant. Furthermore, this approach remains

Halliburton Energy Services v. Smith International
Patent Office Notice

UNITED STATES

FTC Asks Supreme Court to
Review Legality of Patent Settlement
Agreements between Branded
and Generic Manufacturers
On August 29, 2005, the Federal Trade Commission
(FTC) filed a petition for writ of certiorari in the
Supreme Court seeking review of an Eleventh Circuit
Court of Appeals Decision against the FTC. As
reported in the last issue, the Eleventh Circuit had
reversed an FTC cease and desist order and had
upheld the legality of two agreements settling patent
infringement claims between branded manufacturer
Schering-Plough and generic manufacturers
Upsher-Smith and ESI Lederle, respectively.
The FTC seeks review on the question whether “an
agreement between a pharmaceutical patent holder
and a would-be generic competitor, in which the
patent holder makes a substantial payment to the
challenger for the purpose of delaying the challenger’s
entry into the market, is an unreasonable restraint of
trade.” The FTC also takes issue with the Eleventh
Circuit’s application of the standard of review in
rejecting the FTC’s earlier administrative conclusions.

FTC seeks review
on whether an
agreement between
patentee and generic
competitor, involving a
substantial payment to
delay market entry,
is ‘an unreasonable
restraint of trade’.

In its petition, the FTC argues that the Eleventh
Circuit mistakenly held that settlements “within the
outer, nominal bounds of patent claims are presumed
lawful.” The FTC urges that such a rule fails to take
into account the substantial uncertainty in both the
validity and reach of patents. Rather, the FTC believes
that any substantial settlement payment from the
patent holder to the generic manufacturer represents
a “quid pro quo” for an “agreement by the generic
to defer entry beyond the date that represents
an otherwise reasonable litigation compromise,”
reflecting the risk associated with that uncertainty.
The FTC relies heavily on its view that the HatchWaxman Act signaled clear Congressional intent
to foster generic entry and encourage challenges to
blocking patents. That intent overrides, in its view, any
public policy in favor of litigation settlement. It also
cites empirical reports of successful generic challenges
to such blocking patents, and of reduced consumer
cost associated with increased use of generics.
The Supreme Court has full discretion whether
to accept the matter for review. There is no set
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timetable for that determination, but it could well
occur in October or November of this year. If the
petition is granted, additional briefing and argument
would be considered before any ultimate decision.
FTC Petition

EUROPE

European Commission Fines
AstraZeneca 60 Million Euros
for Misuse of Patent System
On June 15, 2005, the European Commission
fined Anglo-Swedish group AstraZeneca €60
million for abusing its dominant position by:
(1) Giving misleading information to several
national patent offices within the EEA in
order to obtain supplementary protection
certificates, giving extended patent
protection for its ulcer drug, Losec; and
(2) (After AstraZeneca switched to a tablet
version of Losec) Asking national agencies
to de-register market authorizations for the
capsule formulation of Losec, preventing generic
producers from offering rival products.

The Commission concluded that these
actions, which took place between 1993 and
2000, made it almost impossible for other
companies to launch competing generic
products (keeping prices artificially high) and
prevented parallel imports, and therefore
amounted to an abuse of a dominant position.
The Commission’s decision could signal a
much stricter approach towards European
pharmaceutical companies. While this type of
conduct has in the past been found to violate US
antitrust law, it is the first time the Commission
has applied Article 82 EC Treaty in this way.
Indeed, a Commission official confirmed that,
because of the novelty of the situation, the “fine
was lower than it would otherwise have been.”
AstraZeneca has appealed the Commission’s
decision to the European Court of First Instance.

of manufacturers of branded pharmaceuticals, that
have been licensed for prescribing on the NHS.
The move comes only months after the PPRS was
renewed until 2005. The study forms part of the
OFT’s examination of public procurement in the UK.
It is expected that the OFT will report on
the findings of the study in Spring 2006. If
the OFT concludes that the PPRS is in need
of reform, it could recommend that the
UK government change the PPRS, refer the
PPRS to the Competition Commission for a
fuller investigation, or take undertakings from
pharmaceutical companies in lieu of a reference.
OFT Review

We would like to give special thanks for this
edition to Corinne Atton, Christian Breuer,
James Burling, Axel Desmedt, Jeffrey Francer,
Christopher Hutton, Lars Klein, Andreas
Seip, Peter Spaeth and Michael Twomey.
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